|
|
|
| |
| |
EDITORIAL |
|
| |
|
Genopole to Welcome Delegates from the Association of University Research Parks in Évry
As part of our 20th anniversary celebrations, Genopole is happy to host on June, 20, 2018 a delegation of members of the Association of University Research Parks (AURP) who will be visiting our biocluster as part of its “Insights into Research Parks” (or I2RP) events.
|
|
|
|
|
|
The AURP was created in 1986 and has over 175 members coming in large proportion from university, governmental, not-for-profit and private organisations interested in the development and promotion of research parks and innovation districts. Genopole is a Sustaining Member of AURP and our Director of International Affairs was elected at the Board of AURP in 2017, also co-chairing its International Committee. Holding an I2RP at Genopole is a first of its kind for AURP, as this event is conducted outside the US for the first time.
Day 1 of the I2RP programme at Genopole will comprise presentations by (and visits to) our principal research laboratories and companies located on our main campus in Évry.
Day 2 of this I2RP will be spent on the campus of Université Paris-Saclay, also located at proximity of Evry, and to which Genopole is associated. We are very much looking forward to hosting AURP members on site, as this event is very much part of Genopole’s thrust towards internationalisation of its connections.
Jean-Marc Grognet, CEO
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NETWORKING |
|
|
|
Genopole Present at BIO-2018
At BIO this year, you will be able to find us at Booth #527.
Five Genopole companies will also be attending BIO-2018, i.e., Algentech, Pep-therapy, Endodiag, Enterome, and Yposkesi.
Come and sample.
French cheese and wine on June 5, 2018 at 5:00pm!
|
 |
|
|
|
|
|
|
|
|
 |
Toronto Health Innovation Week
As Canada’s largest city, Toronto is home to MaRS Discovery District, with key research hospitals, significant research groups such as the Ontario Institute for Cancer Research, a diverse workforce and a growing community of successful health start-ups. This year’s edition of the Toronto Health Innovation Week (THIW) was held on April 9-13.
|
|
|
THIW is the city’s major showcase event for metropolitan players to exchange on the future of health innovation, to meet business partners, to present to investors. THIW also featured a full-day of Life Science Nation’s RESI B-to-B meetings.
Our Director of International Affairs was there to meet Ontario’s Chief Scientist Molly Schoichet, President of Genome Canada Marc Lepage, as well as representatives of MaRS (Toronto’s city center based biocluster), of Ontario Genomics, of Accel-Rx and Teralys.
|
|
|
|
|
nbsp; |
|
|
|
|
|
|
| |
WHAT'S NEW AT GENOPOLE |
|
| |
|
First Car To Use Global Bioenergies’ Renewable Gasoline
On April 5, 2018, for the first time, Global Bioenergies and Audi used an EN228-compliant gasoline blend containing over 34% of renewable isobutene-derived compounds to fuel the Audi A4 2.0 TFSI model on the Montlhéry test circuit.
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NEWS FROM THE BIOCLUSTER COMPANIES |
|
| |
|
 |
Winners of the Concours Mondial d’Innovation 2030 (World Innovation Competition)
Abolis, a Genopole company specialising in synthetic biology, has been selected by Concours Mondial d’Innovation (CMI) for a Phase 2 Award for its Cell Factory project. CMI recognises projects initiated by early-stage companies that are considered as future champions, and that are most likely to generate jobs, wealth and exports.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
EVENTS |
|
| |
Eleven Companies Entering Genopole’s Booster Accelerator, and Shaker Incubation Programs
|
|
| |
|
At the latest April 10, 2018 Welcome Session, Genopole’s CEO, Jean-Marc Grognet, spoke of the beauty and wealth of diversity in greeting the companies that will next enter our Booster (Accelerator) and Shaker (Incubation) programs.
The designated winners of the latest selection round are the following eleven companies : |
|
|
|
|
| |
|
BOOSTER
Neosper (winner of the 2017 Digital Start-up at the University Telecom Sud-Paris - also a partner of Genopole), that develops software to assist surgeons in 3D-led reconstruction procedures.
AgenT, that develops a blood test for early detection of Alzheimer Disease.
|
 |
|
|
|
|
| |
|
EvalDepol, that provides counselling on decontamination solutions.
Agate Santé, that develops a software for management of medical information in kidney transplant.
Biomédé (a graduate of our Shaker program), that develops plant seeds for the extraction of heavy metals from spoiled soils.
Effiscience - ScreenSeed, that applies high throughput screening technology to the identification of molecules of interest in the elucidation of plant germination.
Neurocell, that provides consultancy services and aid devices to improve re-animation in neurological conditions. |
|
|
|
|
| |
|
SHAKER
Oxsam, that develops new techniques to screen and test anti-oxidants.
Iris Fragrances, that targets the production of essential oils extracts by synthetic biology.
Gamma, that develops a blood analytical device. |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
VISITS |
|
| |
Australian-French Entrepreneurship Visiting Genopole |
|
| |
|
 |
Genopole hosted a delegation in Evry of Australian and French students in early April who were part of the Study Tour to France and winners of the second edition of the flagship Australian-French Entrepreneurship Challenge, held in Adelaide in July 2017.
This Challenge was organized with the support of the South Australian government, together with local Universities and the Adelaide innovation scene. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
SCIENTIFIC NEWS |
|
| |
|
|
| |
|
Nanoproteomic Analyzer
As reported by Nature Communications, scientists from the Université d'Évry-Val-d'Essonne's Lambe (Laboratory for the Analysis and Modeling in Biology and the Environment) and of the Université de Cergy-Pontoise, Hôpital Lariboisière and Excilone have developed a device to detect and characterise trace concentrations of proteins. |
 |
This device is built on a nanoporous proteinic material and is integrated in an electrodes-driven automated system that produces electrical signatures that are specific to sequence and size of proteins. It can also recognise short peptides, even down to the tens of molecules.
Based on the results obtained with this device’s prototype, the hope is that it can be used for the detection of disease biomarkers that remain undetectable with current methods in biological fluids, as well as to measure protein contents in single cells in circulation or in extracellular bodies. |
|
|
|
|
|
|
|
|
|
|
|
|
|
